My 2023 biotech outlook calls for ongoing momentum in title variations. I just will need to determine out what the shares will do.
Last yr, Respira Technologies turned Qnovia. It’s run by a previous tobacco government with vape working experience, and it is building an inhaled nicotine system for quitting smoking cigarettes. On 1 hand, I found a long time ago that a very very good platform for that is just to not inhale any a lot more nicotine. But on the other hand, going from Q straight to N in a company name sounds clinically promising.
My 2023 biotech outlook calls for ongoing momentum in title variations. I just will need to determine out what the shares will do.
Last yr, Respira Technologies turned Qnovia. It’s run by a previous tobacco government with vape working experience, and it is building an inhaled nicotine system for quitting smoking cigarettes. On 1 hand, I found a long time ago that a very very good platform for that is just to not inhale any a lot more nicotine. But on the other hand, going from Q straight to N in a company name sounds clinically promising.
